Introduction of Peace River Biotechnology Company Limited
Peace River Biotechnology Company Limited is a relatively new member of the biotechnology industry. Its headquarters is located in Harbin, Heilongjiang province. It is an all Chinese company producing world class product made in China. The initial marketing offer from the Company is a series of primary binding assays for detection of antibody to Brucella sp. in virtually all mammalian species of hosts. Brucellosis is a highly contagious zoonotic disease which infects both man and animals. Control of brucellosis is only possible by removal of all infected animals from the vicinity of unexposed animals. Detection of all infected animals cannot be accomplished using older diagnostic tests such as the Rose Bengal agglutination test or the standard tube agglutination test. Therefore, Peace River Biotechnology Company Limited has collaborated with an OIE Brucellosis Reference Laboratory to make available more accurate tests, tests that must replace the older tests for China to be able to control brucellosis. These tests all conform to OIE standards and have been tested by an OIE Reference Laboratory for Brucellosis and found to be excellent, in fact superior when compared to other commercially available antibody assays for brucellosis. It is important that these assays are produced in China as this allows: Faster delivery; Provides very rapid technical backup.
Bovine brucellosis is usually caused by Brucella abortus, less frequently by B. melitensis, and by B. suis. Infection is widespread globally. Several countries in Northern and Central Europe, Canada, Japan, Australia and New Zealand are believed to be free from the agent.
Clinically, the disease is characterised by one or more of the following signs: abortion, retained placenta, orchitis, epididymitis and, rarely, arthritis, with excretion of the organisms in uterine discharges and in milk. Diagnosis depends on the isolation of Brucella from abortion material, udder secretions or from tissues removed at post-mortem. Presumptive diagnosis can be made by assessing specific cell-mediated or serological responses to Brucella antigens.
Brucella abortus, B. melitensis and B. suis are highly pathogenic for humans, and all infected tissues, cultures and potentially contaminated materials must be handled under appropriate containment conditions.
Identification of the agent: Presumptive evidence of Brucella is provided by the demonstration, by modified acid-fast staining of organisms, of Brucella morphology in abortion material or vaginal discharge, especially if supported by serological tests. The recently developed polymerase chain reaction methods provide additional means of detection. Whenever possible, Brucella spp. should be isolated using plain or selective media by culture from uterine discharges, aborted fetuses, udder secretions or selected tissues, such as lymph nodesand male and female reproductive organs.. Species and biovars should be identified by phage lysis, and by cultural, biochemical and serological criteria. Molecular methods have recently been introduced as additional biotyping methods.
Serological and allergic skin tests: The buffered Brucella antigen tests, i.e. rose bengal test and buffered plate agglutination test, the complement fixation test, the enzyme-linked immunosorbent assay (ELISA) or the fluorescence polarisation assay, are suitable tests for screening herds and individual animals. However, no single serological test is appropriate in each and all epidemiological situations. Therefore, the reactivity of samples that are positive in screening tests should be confirmed using an established confirmatory strategy. The indirect ELISA or milk ring test performed on bulk milk samples are effective for screening and monitoring dairy cattle for brucellosis, but the milk ring test is less reliable in large herds. Another immunological test is the brucellin skin test, which can be used as a screening or as a confirmatory herd test when positive serological reactors occur in the absence of obvious risk factors in unvaccinated herds. Interferon gamma tests, precipitin tests using native hapten antigen and indirect ELISA using rough lipopolysaccharide antigen have shown promise in differentiating brucellosis from exposure to cross reacting microorganisms.
Requirements for vaccines and diagnostic biologicals: Brucella abortus strain 19 remains the reference vaccine to which any other vaccines are compared. It should be prepared from US-derived seed cultures, and each batch must conform to minimum standards for viability, smoothness, residual virulence and ability to immunise mice against challenge with a virulent strain of B. abortus. Brucella abortus strain RB51 vaccine was produced from a laboratory-derived rough mutant of smooth B. abortus strain 2308. However, its efficiency in cattle and its innocuousness remain controversial. Brucellin preparations for the intradermal test must be free of smooth lipopolysaccharide and must not produce nonspecific inflammatory reactions or interfere with serological tests. Diagnostic antigens must be prepared from smooth strains of B. abortus, strain 1119-3 or strain 99 and comply with minimum standards for purity, sensitivity and specificity. (Chapter 2.3.1.bovine brucellosis OIE manual, 2004)